EUVIMEDEUVIMED entdecken
Crossref

Impact of combined pregabalin and multimodal analgesia on cancer pain and quality of life in advanced colorectal cancer

Xiao-Yu Wang, Zhan-Dong Wang, Kuo Kan, Xin-Xin Guo

World Journal of Gastrointestinal Oncology · 15.08.2026 · 18 (8)

DOI: 10.4251/wjgo.120486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.08.2026. Verfasst von Xiao-Yu Wang und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Colorectal cancer has high morbidity and mortality, with over 70% patients suffering from cancer pain. Advanced cases have complex pain mechanisms with neuropathic and nociceptive pain superposition. Conventional multimodal analgesia has limitations: Opioids cause adverse reactions, with poor pain control and frequent breakthrough pain in some patients, severely impairing quality of life. Pregabalin is effective for neuropathic pain, and its combined application value needs exploration. AIM To explore pregabalin plus multimodal analgesia's effects on advanced colorectal cancer pain and life quality. METHODS Total of 100 advanced colorectal cancer patients with moderate to severe pain in our hospital were selected and randomly divided into two groups (50 cases in each group): Guideline-based multimodal analgesia was used as the control, and the observation group was added with pregabalin. A 12-week intervention was conducted; numerical rating scale, cancer patient quality of life core scale, breakthrough pain, opioid dose, and adverse effects were recorded. RESULTS Both groups showed significant post-intervention declines in numerical rating scale scores, breakthrough pain frequency and daily opioid dosage (all P < 0.05); the observation group had lower levels [2.3 ± 0.8 points vs 3.7 ± 1.0 points, 0.4 ± 0.3 episodes per day vs 1.5 ± 0.6 episodes per day, 85.6 ± 20.3 mg oral morphine milligram equivalents vs 132.4 ± 25.6 mg oral morphine milligram equivalents, all P < 0.001]. Its cancer patient quality of life core scale overall score was markedly higher (68.5 ± 10.2 vs 52.4 ± 9.6, P < 0.001). Adverse reactions were relieved symptomatically, no severe events occurred. CONCLUSION Pregabalin plus multimodal analgesia relieves pain, cuts opioids and boosts life quality in advanced colorectal cancer safely.

Zitieren

APA

Wang, X., Wang, Z., Kan, K., & Guo, X. (2026). Impact of combined pregabalin and multimodal analgesia on cancer pain and quality of life in advanced colorectal cancer. World Journal of Gastrointestinal Oncology, 18(8). https://doi.org/10.4251/wjgo.120486

Vancouver

Wang X, Wang Z, Kan K, Guo X. Impact of combined pregabalin and multimodal analgesia on cancer pain and quality of life in advanced colorectal cancer. World Journal of Gastrointestinal Oncology. 2026;18(8). doi:10.4251/wjgo.120486

BibTeX
@article{Wang2026,
  author = {Wang, Xiao-Yu and Wang, Zhan-Dong and Kan, Kuo and Guo, Xin-Xin},
  title = {Impact of combined pregabalin and multimodal analgesia on cancer pain and quality of life in advanced colorectal cancer},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4251/wjgo.120486}
}
Kostenlos starten →